Telomerase Contributes to Fludarabine Resistance in Primary Human Leukemic Lymphocytes

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Shawi, May ^a,b   Chu, Tsz Wai ^a,b   Martinez Marignac, Veronica ^c   Yu, Y ^f   Gryaznov, Sergei M ^d   Johnston, James B ^e   Lees Miller, Susan P ^f   Assouline, Sarit E ^a,c   Autexier, Chantal ^a,b   Aloyz, Raquel ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d GERON CORPORATION   (United States)

^e UNIVERSITY OF MANITOBA   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; IMETELSTAT; KU ANTIGEN; KU80 PROTEIN; OLIGONUCLEOTIDE; TELOMERASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BINDING SITE; CANCER RESISTANCE; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MALE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SENSITIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 17; DNA HELICASES; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONES; HUMANS; INDOLES; LEUKEMIA, LYMPHOID; MIDDLE AGED; NIACINAMIDE; PHOSPHORYLATION; PROTEIN BINDING; TELOMERASE; VIDARABINE;

EID: 84880795032     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070428     Document Type: Article

References (52)

1. Moreno C, Montserrat E, (2008) New prognostic markers in chronic lymphocytic leukemia. Blood Rev 22: 211-219.
2. Caligaris-Cappio F, (1996) B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood 87: 2615-2620.
3. Bechter OE, Eisterer W, Pall G, Hilbe W, Kuhr T, et al. (1998) Telomere Length and Telomerase Activity Predict Survival in Patients with B Cell Chronic Lymphocytic Leukemia. Cancer Res 58: 4918-4922.
4. Trentin L, Ballon G, Ometto L, Perin A, Basso U, et al. (1999) Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. Br J Haematol 106: 662-668.
5. Damle RN, Batliwalla FM, Ghiotto F, Valetto A, Albesiano E, et al. (2004) Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood 103: 375-382.
6. Ricca I, Rocci A, Drandi D, Francese R, Compagno M, et al. (2007) Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. Leukemia 21: 697-705.
7. Terrin L, Trentin L, Degan M, Corradini I, Bertorelle R, et al. (2007) Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome. Leukemia 21: 965-972.
8. Rampazzo E, Bonaldi L, Trentin L, Visco C, Keppel S, et al. (2012) Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. Haematologica 97: 56-63.
9. Autexier C, Lue NF, (2006) The structure and function of telomerase reverse transcriptase. Annu Rev Biochem 75: 493-517.
10. Akiyama M, Yamada O, Kanda N, Akita S, Kawano T, et al. (2002) Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors. Cancer Lett 178: 187-197.
11. Harley CB, (2008) Telomerase and cancer therapeutics. Nat Rev Cancer 8: 167-179.
12. Bollmann FM, (2008) The many faces of telomerase: emerging extratelomeric effects. Bioessays 30: 728-732.
13. Zhang P, Dilley C, Mattson MP, (2007) DNA damage responses in neural cells: Focus on the telomere. Neuroscience 145: 1439-1448.
14. Obermann EC, Went P, Tzankov A, Pileri SA, Hofstaedter F, et al. (2007) Cell cycle phase distribution analysis in chronic lymphocytic leukaemia: a significant number of cells reside in early G1-phase. J Clin Pathol 60: 794-797.
15. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S, (1995) Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 85: 2315-2320.
16. Elter T, Hallek M, Engert A, (2006) Fludarabine in chronic lymphocytic leukaemia. Expert Opin Pharmacother 7: 1641-1651.
17. Sampath D, Plunkett AW, (2007) The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance. Curr Oncol Rep 9: 361-367.
18. Willmore E, Elliott SL, Mainou-Fowler T, Summerfield GP, Jackson GH, et al. (2008) DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. Clin Cancer Res 14: 3984-3992.
19. Pettitt AR, Clarke AR, Cawley JC, Griffiths SD, (1999) Purine analogues kill resting lymphocytes by p53-dependent and-independent mechanisms. Br J Haematol 105: 986-988.
20. de Campos-Nebel M, Larripa I, Gonzalez-Cid M, (2008) Non-homologous end joining is the responsible pathway for the repair of fludarabine-induced DNA double strand breaks in mammalian cells. Mutat Res 646: 8-16.
21. Gu J, Lieber MR, (2008) Mechanistic flexibility as a conserved theme across 3 billion years of nonhomologous DNA end-joining. Genes Dev 22: 411-415.
22. Ting NS, Pohorelic B, Yu Y, Lees-Miller SP, Beattie TL, (2009) The human telomerase RNA component, hTR, activates the DNA-dependent protein kinase to phosphorylate heterogeneous nuclear ribonucleoprotein A1. Nucleic Acids Res 37: 6105-6115.
23. Ting NS, Yu Y, Pohorelic B, Lees-Miller SP, Beattie TL, (2005) Human Ku70/80 interacts directly with hTR, the RNA component of human telomerase. Nucleic Acids Res 33: 2090-2098.
24. Wang Y, Ghosh G, Hendrickson EA, (2009) Ku86 represses lethal telomere deletion events in human somatic cells. Proc Natl Acad Sci U S A 106: 12430-12435.
25. Li G, Nelsen C, Hendrickson EA, (2002) Ku86 is essential in human somatic cells. Proc Natl Acad Sci U S A 99: 832-837.
26. Poncet D, Belleville A, t'kint de Roodenbeke C, Roborel de Climens A, Ben Simon E, et al. (2008) Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. Blood 111: 2388-2391.
27. Herbert B-S, Gellert GC, Hochreiter A, Pongracz K, Wright WE, et al. (2005) Lipid modification of GRN163, an N3′- >P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 24: 5262-5268.
28. Amrein L, Hernandez TA, Ferrario C, Johnston J, Gibson SB, et al. (2008) Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. Br J Haematol 143: 698-706.
29. Jackson SR, Zhu CH, Paulson V, Watkins L, Dikmen ZG, et al. (2007) Antiadhesive effects of GRN163L - an oligonucleotide N3′->P5′ thio-phosphoramidate targeting telomerase. Cancer Res 67: 1121-1129.
30. Bachand F, Triki I, Autexier C, (2001) Human telomerase RNA-protein interactions. Nucleic Acids Res 29: 3385-3393.
31. Goodarzi AA, Lees-Miller SP, (2004) Biochemical characterization of the ataxia-telangiectasia mutated (ATM) protein from human cells. DNA Repair (Amst) 3: 753-767.
32. Autexier C, Triki I, (1999) Tetrahymena telomerase ribonucleoprotein RNA-protein interactions. Nucleic Acids Res 27: 2227-2234.
33. Amrein L, Loignon M, Goulet AC, Dunn M, Jean-Claude B, et al. (2007) Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase. J Pharmacol Exp Ther 321: 848-855.
34. Amrein L, Rachid Z, Jean-Claude B, Soulieres D, Aloyz R, et al. (2011) ZRF4, a combi-molecule with increased efficacy as compared with the individual components in chronic lymphocytic leukemia lymphocytes in vitro. Leukemia 25: 1512-1516.
35. Hebb J, Assouline S, Rousseau C, Desjardins P, Caplan S,et al. (2010) A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients. Cancer Chemother Pharmacol.
36. Morabito F, Stelitano C, Callea I, Dattola A, Console G, et al. (1998) In vitro drug-induced cytotoxicity predicts clinical response to fludarabine in B-cell chronic lymphocytic leukaemia. Br J Haematol 102: 528-531.
37. Sellmann L, de Beer D, Bartels M, Opalka B, Nuckel H, et al. (2011) Telomeres and prognosis in patients with chronic lymphocytic leukaemia. Int J Hematol 93: 74-82.
38. Ratain MJ, Kelsey S, Janisch L, Smith J, Go N, et al. (2010) Imetelstat sodium (GRN163L), a telomerase inhibitor: tolerability, pharmacokinetics and pharmacodynamic activity using an intermittent once every four weeks dosing schedule in patients with advanced solid tumors. Ejc Supplements 8: 123-123.
39. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, et al. (2001) p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 98: 814-822.
40. Deaglio S, Capobianco A, Bergui L, Durig J, Morabito F, et al. (2003) CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 102: 2146-2155.
41. Asai A, Oshima Y, Yamamoto Y, Uochi TA, Kusaka H, et al. (2003) A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res 63: 3931-3939.
42. Pascolo E, Wenz C, Lingner J, Hauel N, Priepke H, et al. (2002) Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem 277: 15566-15572.
43. Ward RJ, Autexier C, (2005) Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol Pharmacol 68: 779-786.
44. Christodoulopoulos G, Muller C, Salles B, Kazmi R, Panasci L, (1998) Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin. Cancer Res 58: 1789-1792.
45. Wu XP, Smavadati S, Nordfjall K, Karlsson K, Qvarnstrom F, et al. (2012) Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks. Biochimica Et Biophysica Acta-Molecular Cell Research 1823: 2130-2135.
46. Muller C, Paupert J, Monferran S, Salles B, (2005) The double life of the Ku protein: facing the DNA breaks and the extracellular environment. Cell Cycle 4: 438-441.
47. Moll U, Lau R, Sypes MA, Gupta MM, Anderson CW, (1999) DNA-PK, the DNA-activated protein kinase, is differentially expressed in normal and malignant human tissues. Oncogene 18: 3114-3126.
48. Choi EK, Lee YH, Choi YS, Kwon HM, Choi MS, et al. (2002) Heterogeneous expression of Ku70 in human tissues is associated with morphological and functional alterations of the nucleus. Journal of Pathology 198: 121-130.
49. Zhao Y, Abreu E, Kim J, Stadler G, Eskiocak U, et al. (2011) Processive and distributive extension of human telomeres by telomerase under homeostatic and nonequilibrium conditions. Mol Cell 42: 297-307.
50. Cristofari G, Adolf E, Reichenbach P, Sikora K, Terns RM, et al. (2007) Human telomerase RNA accumulation in Cajal bodies facilitates telomerase recruitment to telomeres and telomere elongation. Mol Cell 27: 882-889.
51. Brennan SK, Wang Q, Tressler R, Harley C, Go N,et al. (2010) Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One 5.
52. Austen B, Powell JE, Alvi A, Edwards I, Hooper L, et al. (2005) Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 106: 3175-3182.